Innovative antibody shows promise for personalised cancer treatment
Scientists from Uppsala University and KTH Royal Institute of Technology have developed a new type of antibody that could lead to safer and more effective cancer treatments.
This ‘3-in-1’ antibody works by combining three important functions: targeting cancer cells, delivering a drug directly to these cells, and activating the immune system to attack the cancer cells more strongly.
This research, published in Nature Communications, describes how the antibody boosts the effect of T cells – the body’s natural cancer-fighting cells – on tumours. The antibody both targets specific mutations found only in cancer cells (called neoantigens) and stimulates immune cells, which increases their response against the tumour.
Lead authors Sara Mangsbo, Professor at the Department of Pharmacy at Uppsala University, and Johan Rockberg, Professor at KTH, explain that this approach is designed for precision medicine, where treatments are tailored to each patient’s cancer. The new antibody has shown promising results in early tests; in blood samples, it activated the right immune cells and in animal tests it extended survival in mice and, at higher doses, even helped prevent some from developing cancer. Importantly, this approach also appears safer than many current treatments.
Additionally, the drug is designed to be easier and faster to produce. It consists of two parts: a bispecific antibody that can be mass-produced, and a custom-made peptide that can be quickly prepared for each patient’s specific cancer. According to Rockberg, “This setup reduces production costs and shortens the time needed to tailor the drug for individual patients, allowing them to start treatment sooner.”
The team’s goal is to create a cancer treatment that is more flexible, faster acting, and safer than existing options. Next, they plan to prepare the drug for human safety studies, with the aim of beginning clinical trials soon.
“We have been researching precision medicine for close to 15 years now, as well as how we can use antibodies to influence an important key protein (CD40) in the immune system,” commented Mangsbo. “We can now show that our new antibody method works as precision medicine for cancer.”
Source:
New antibody could be promising cancer treatment [Accessed November 12, 2024] https://www.eurekalert.org/news-releases/1064404
Related News
-
News AI-driven drug discovery model sets new accuracy prediction benchmark
Iambic Therapeutics, an Nvidia-backed biotech based in London, have stated that their AI drug discovery model named ‘Enchant’ demonstrates the potential to reduce the time and cost associated with new drug development. -
News Biopharmaceutical manufacturing boost part of new UK government budget
In their national budget announced by the UK Labour Party, biopharmaceutical production and manufacturing are set to receive a significant boost in capital grants through the Life Sciences Innovative Manufacturing Fund (LSIMF). -
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News CPHI Pharma Awards 2024: Meet the winners from the CPHI Celebration
This year we had a lot to celebrate, the 35th Anniversary of CPHI, and our esteemed award winners, of which we included two additional categories this year, the Future Leader award, and Woman of the Year award. -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance